Pyrone-Based Inhibitors of Metalloproteinase Types 2 and 3 May Work as Conformation-Selective Inhibitors
2011

Pyrone-Based Inhibitors of Metalloproteinase Types 2 and 3

publication Evidence: moderate

Author Information

Author(s): Jacob D Durrant, César A F de Oliveira, J Andrew McCammon

Primary Institution: University of California at San Diego

Hypothesis

Can accounting for protein dynamics improve the prediction of binding affinity and selectivity of metalloproteinase inhibitors?

Conclusion

The study suggests that accounting for protein dynamics is essential for accurately predicting the binding affinity and selectivity of metalloproteinase inhibitors.

Supporting Evidence

  • Matrix metalloproteinases are involved in various human diseases.
  • Only one MMP inhibitor has been approved by the FDA due to selectivity issues.
  • Accounting for protein flexibility can improve the accuracy of virtual screening.
  • Different dynamics of MMP-2 and MMP-3 explain the selectivity of the AM-6 compound.

Takeaway

This study found that some drugs work better on certain proteins because the proteins can change shape. By understanding how these proteins move, scientists can design better drugs.

Methodology

The study used molecular dynamics simulations and docking studies to evaluate the binding modes and affinities of inhibitors to metalloproteinases.

Limitations

The study primarily focuses on the dynamics of MMP-2 and MMP-3 and may not generalize to other metalloproteinases.

Digital Object Identifier (DOI)

10.1111/j.1747-0285.2011.01148.x

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication